Exclusive Summary

• - Fully off-patent with mature OTC/Rx pathways; the 2%/8 mL spec aligns with UK/Commonwealth labeling and use.
• - Targets hundreds of millions with allergic conjunctivitis plus pediatric VKC clusters in high-prevalence regions, with predictable seasonal peaks.
• - Strong safety, steroid-sparing and prophylactic value make it suitable for children and long-term maintenance.
• - Despite crowded competition, differentiation via preservative-free packs, child-friendly labeling, small seasonal packs, and reliable supply is feasible.
• - Off-patent and cost-efficient manufacturing typically deliver a 30–70% price advantage versus branded dual-action drops, supporting high-volume OTC sell-through.